Targeting the Warburg Effect with Glucose Mutation Theory in Post-Cystectomy, Chemotherapy-Contraindicated Cases: A Case Study of a 72-Year-Old Female Treated with Glucosodiene Over a 20-Day Period

Abstract

This manuscript delves into the intricate landscape of bladder cancer, highlighting the challenges of early detection and the nuanced considerations involved in chemotherapy decision-making based on patient-specific factors. The Maher Akl's groundbreaking Glucose Mutation Theory presents Glucosodiene as a promising breakthrough. The case presentation meticulously details the journey of a 72-year-old woman diagnosed with high-grade papillary urothelial carcinoma, spanning from initial diagnosis to postoperative outcomes. In the face of Bacillus Calmette-Guérin (BCG) therapy failure, Glucosodiene emerges as a safe and reliable alternative, offering a novel and effective treatment avenue, especially in cases where traditional chemotherapy is contraindicated. This approach advocates for Glucosodiene as a primary therapeutic option after the shortcomings of conventional treatments, instilling confidence in its efficacy and safety, particularly for cases deemed ineligible for chemotherapy.